Preliminary Agenda Now Available

The growing acceptance and availability of cell-free DNA-based screening from maternal blood is having a dramatic impact on prenatal testing. One result has been the steady decline in the number of women choosing invasive testing, with growing shift away from karyotyping in favor of arrays, or in some cases sequencing, for analysis of these samples. The range of approaches being employed for cell-free DNA testing continues to grow, including the release of kits for in-house analysis and so-called second generation assays that provide much improved detection of sub-chromosomal anomalies. There has been a push to expand NIPT use beyond higher-risk pregnancies, as well as extending the range of genetic conditions reported from the tests, but such changes come at a price.

Research into testing based on isolation of fetal cells from maternal blood has been underway for decades, and the discussion has been couched in terms of “if this approach can be commercialized”. At this meeting last year, for the first time, the conversation shifted to “when this approach is commercialized” as numerous groups reported substantial progress in achieving reliable isolation that would make this possible.

Updated comparisons and examination of these issues, and the implementation of these different approaches, will again make for lively discussion and insight into where this field is headed and ways for researchers, test providers, clinicians and clinics to take these developments into consideration.


Dennis LoSpecial Keynote Presentation: Pushing Towards the Limit for Non-Invasive Prenatal Testing

Y.M. Dennis Lo, Ph.D., Chairman, Chemical Pathology and Director, Li Shing Institute of Health Science, The Chinese University of Hong Kong



Preliminary Agenda

Overview

Trends and Implications for Fetal Anomalies: Beyond the Karyotype

Ronald Wapner, M.D., Director, Reproductive Genetics and Vice Chair, Research, Department of Obstetrics & Gynecology, Columbia University Medical Center

The Impact of Health Economic Evidence on the Coverage and Reimbursement of New Prenatal Diagnostics

Mark Girardi, Vice President, Market Access, GfK Health

Dealing with VOUS in Prenatal Testing

Ignatia Van den Veyer, M.D., Professor, Maternal-Fetal Medicine & Genetics, Baylor College of Medicine (invited)

Perspectives and Challenges of Genetic Counseling in the Prenatal Setting

Speaker to be Announced


Isolation and Analysis of Fetal Cells from Maternal Blood

New Results Using NGS and Circulating Trophoblasts

Dr. Patrizia Paterlini-Brechot, Ph.D., Cellular & Molecular Biology, University of Paris Descartes (France)

Enrichment and Characterization of Fetal Cells from Maternal Blood

Speaker to be Announced, ARCEDI Biotech ApS (Denmark)

Analysis of Small Quantities of Fetal Cells for Prenatal Diagnosis

Art Beaudet, M.D., Chair, Department of Molecular & Human Genetics, Baylor College of Medicine

NanoVelcro Chips for Isolation and Characterization of Circulating Fetal Nucleated Cells – Toward Noninvasive Prenatal Diagnostics

Hsian-Rong Tseng, Ph.D., Professor, Molecular & Medical Pharmacology, University of California Los Angeles

Advanced Method for Whole Genome Amplification and Application to Limited Samples

Xiaoliang “Sunney” Xie, Ph.D., Department of Chemistry, Harvard University


Roundtable Breakout Discussions

  • Can or Should Any Current Prenatal Testing Components Be Replaced?
  • Ethical and Genetic Counselling Challenges for Prenatal Testing
  • Intellectual Property Issues with New Prenatal Testing Technologies
  • Economics of Prenatal Testing Options and Reimbursement
  • Implications for Expanding Cell-Free DNA Screening for Lower Risk Mothers
  • Commercial Potential for Non-Invasively Obtained Fetal Cells
  • Prenatal Testing beyond Common Aneuploidies
  • Bioinformatics Issues for Sequence-Based Testing
  • Developing Biomarkers for Preeclampsia and Pre-Term Birth


Cell-Free DNA Screening

KEYNOTE PRESENTATION:
Pushing towards the Limit for Non-Invasive Prenatal Testing

Y.M. Dennis Lo, Ph.D., Chairman, Chemical Pathology and Director, Li Shing Institute of Health Science, The Chinese University of Hong Kong

Resource and Policy Implications of Extending NIPS to Lower-Risk Pregnancies

Megan Allyse, Ph.D., Assistant Professor of Biomedical Ethics, The Mayo Clinic

What Cell-Free DNA Screening Can’t Do

Mark Evans, M.D., Professor, Obstetrics & Gynecology, Mount Sinai School of Medicine, and Comprehensive Genetics

IP issues in the Cell-Free DNA Testing Space

Konstantin Linnik, Ph.D., Partner, Intellectual Property, Nutter, McClennan & Fish LLP

Strategies and Structures Needed to Ensure Patients’ Informed Access to NIPS

Ruth Farrell, M.D., Department of Obstetrics & Gynecology, Cleveland Clinic Foundation

Fragment Endpoints Reveal the Tissues of Origin of Circulating DNA

Matthew Snyder, Ph.D., University of Washington

Panel Discussion with Cell-Free DNA Screening Providers

Illumina: Invited
Natera: Solomon Moshkevich, Vice President, Product & Strategy
Premaitha Health: Peter Collins, Chief Commercial Officer
Quest Diagnostics: Invited
Roche/Ariosa Diagnostics: Invited
Sequenom: Invited


Biomarkers of Preeclampsia and Pre-Term Birth

Biomarkers for Assessing the Risk of Preeclampsia

Speaker to be Announced

Biomarkers for Assessing the Risk of Pre-Term Birth

Speaker to be Announced


Closing Panel: Predicting the Landscape for Prenatal Molecular Diagnostics: The Next Few Years

Art Beaudet, M.D., Chair, Department of Molecular & Human Genetics, Baylor College of Medicine

Mark Evans, M.D., Professor, Obstetrics & Gynecology, Mount Sinai School of Medicine, and Comprehensive Genetics

Cynthia Morton, Ph.D., William Lambert Richardson Professor of Obstetrics, Gynecology & Reproductive Biology, and Professor, Pathology, Harvard Medical School; Director, Cytogenetics, Brigham and Women’s Hospital

Joe Leigh Simpson, M.D., Senior Vice President, Research & Global Programs, March of Dimes Foundation

Ronald Wapner, M.D., Director, Reproductive Genetics and Vice Chair, Research, Department of Obstetrics & Gynecology, Columbia University Medical Center



Program Advisors

David LedbetterCamera Icon PNDXDavid H. Ledbetter, Ph.D., FACMG, Executive Vice President and CSO, Geisinger Health System

Joe_SimpsoCamera Icon PNDXJoe Leigh Simpson, M.D., Senior Vice President for Research and Global Programs, March of Dimes Foundation

 

arthur_beaudetArthur Beaudet, M.D., Chair, Department of Molecular & Human Genetics, Baylor College of Medicine

Cynthia_MortonCynthia Morton, Ph.D., William Lambert Richardson Professor of Obstetrics, Gynecology & Reproductive Biology and Professor of Pathology, Harvard Medical School; Director, Cytogenetics, Brigham & Women’s Hospital

Ronald_WapnerCamera Icon PNDXRonald J. Wapner, M.D., Director, Reproductive Genetics & Vice Chair, Research, Department of Obstetrics & Gynecology, Columbia University Medical Center




For more details on the conference, please contact:

Phillips Kuhl
President
Cambridge Healthtech Institute
Phone: (+1) 781-972-5410
Email: pkuhl@healthtech.com

For partnering and sponsorship information, please contact:

Ilana Quigley
Senior Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-5457
Email: iquigley@healthtech.com